OncRef

Clinical Trial: NCT02947347

Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:Pharmacyclics LLC.
Information Provided By:Pharmacyclics LLC.
Last Update Posted:2026-03-17

Study Overview

Brief Summary

This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study to evaluate the efficacy and safety of ibrutinib in combination with rituximab versus placebo in combination with rituximab in treatment naïve participants with follicular lymphoma (FL).

Official Title

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Naïve Subjects With Follicular Lymphoma (PERSPECTIVE)

Conditions

Follicular Lymphoma

Intervention / Treatment

  • Drug: Ibrutinib Oral Capsule
  • Drug: Placebo
  • Drug: Rituximab

Other Study ID Numbers

  • PCYC-1141-CA
  • 2016-003202-14
  • 2023-507271-21-00
  • 2023
  • 2016

Start Date (Actual)

2017-01-23

Primary Completion Date (Actual)

2024-02-21

Study Completion Date (Actual)

2025-06-09

Enrollment (Actual)

445

Study Type

Interventional

Phase

Phase 3